Profile data is unavailable for this security.
About the company
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
- Revenue in USD (TTM)0.00
- Net income in USD-38.77m
- Incorporated2002
- Employees32.00
- LocationAcasti Pharma Inc3009Boul. De La Concorde East, Suite 102LAVAL H7E 2B5CanadaCAN
- Phone+1 (450) 686-4555
- Fax+1 (450) 686-2505
- Websitehttps://www.acasti.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 22.86m | 8.00 | -- | 2.27 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Lisata Therapeutics Inc | 0.00 | -20.05m | 23.01m | 25.00 | -- | 0.5352 | -- | -- | -2.46 | -2.46 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -35.01 | -45.97 | -38.40 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -35.58m | 23.34m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -118.12 | -- | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | -- | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 23.35m | 109.00 | -- | 0.3013 | -- | 13.90 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 24.37m | 298.00 | -- | 0.5694 | -- | 0.5244 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| NanoViricides Inc | 0.00 | -9.36m | 24.38m | 7.00 | -- | 2.11 | -- | -- | -0.8004 | -0.8004 | 0.00 | 0.9828 | 0.00 | -- | -- | 0.00 | -55.47 | -43.54 | -57.90 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 24.85m | 19.00 | -- | 1.04 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 25.19m | 63.00 | -- | -- | -- | -- | -3.63 | -3.63 | 0.00 | -2.57 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 25.28m | 32.00 | -- | 0.3909 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| TherapeuticsMD Inc | 1.20m | -6.20m | 25.60m | 1.00 | -- | 0.8931 | -- | 21.35 | -0.58 | -0.6955 | 0.1103 | 2.49 | 0.0236 | -- | 0.4556 | 1,199,000.00 | -12.19 | -53.35 | -16.34 | -111.61 | 73.89 | 86.67 | -516.93 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 25.63m | 27.00 | -- | 1.12 | -- | 22.27 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 25.99m | 3.00 | -- | 0.9906 | -- | 60.24 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Biora Therapeutics Inc | 4.00k | -124.33m | 26.18m | 58.00 | -- | -- | -- | 6,546.11 | -8.57 | -8.56 | 0.0003 | -4.28 | 0.00009 | -- | 0.0048 | 68.97 | -293.45 | -122.84 | -- | -369.01 | -- | -- | -3,108,350.00 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| bioAffinity Technologies Inc | 2.53m | -7.94m | 26.35m | 75.00 | -- | 4.37 | -- | 10.40 | -0.9036 | -0.9036 | 0.2895 | 0.5168 | 0.2482 | 144.95 | 6.16 | 33,766.67 | -77.80 | -- | -93.28 | -- | 31.26 | -- | -313.41 | -- | 1.76 | -- | 0.1983 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Acasti Pharma Inc's reporting currency: US Dollar USD
13.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Mar 2024 | 497.36k | 5.29% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 494.70k | 5.26% |
| Adar1 Capital Management LLCas of 31 Mar 2024 | 217.38k | 2.31% |
| G1 Execution Services LLCas of 31 Mar 2024 | 36.65k | 0.39% |
| RBC Capital Markets LLC (Investment Management)as of 31 Mar 2024 | 12.00k | 0.13% |
| National Bank Financial, Inc.as of 31 Mar 2024 | 2.90k | 0.03% |
| Subversive Capital Advisor LLCas of 09 May 2024 | 2.08k | 0.02% |
| UBS Securities LLCas of 31 Mar 2024 | 1.95k | 0.02% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.85k | 0.02% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 584.00 | 0.01% |
More ▼
Data from 31 Mar 2024 - 09 May 2024Source: FactSet Research Systems Inc.
